HC Wainwright reiterated their neutral rating on shares of Sutro Biopharma (NASDAQ:STRO - Free Report) in a report published on Monday morning, Marketbeat.com reports. HC Wainwright currently has a $2.00 price target on the stock, down from their prior price target of $12.00. HC Wainwright also issued estimates for Sutro Biopharma's Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.68) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at ($0.13) EPS and FY2029 earnings at ($0.09) EPS.
STRO has been the topic of several other reports. Wedbush cut Sutro Biopharma from an "outperform" rating to a "neutral" rating and lowered their price target for the company from $8.00 to $2.00 in a research report on Friday, March 14th. Bank of America lowered Sutro Biopharma from a "buy" rating to an "underperform" rating and lowered their target price for the stock from $11.00 to $1.00 in a report on Friday, March 14th. Citizens Jmp downgraded shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a report on Friday, March 14th. JMP Securities restated a "market outperform" rating and set a $17.00 target price on shares of Sutro Biopharma in a report on Wednesday, December 11th. Finally, Wells Fargo & Company cut their price objective on Sutro Biopharma from $5.00 to $4.00 and set an "equal weight" rating for the company in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Sutro Biopharma presently has an average rating of "Hold" and a consensus price target of $6.63.
Check Out Our Latest Report on Sutro Biopharma
Sutro Biopharma Trading Down 3.7 %
STRO traded down $0.03 on Monday, reaching $0.77. The company had a trading volume of 1,776,000 shares, compared to its average volume of 969,028. The company has a market capitalization of $63.24 million, a P/E ratio of -0.48 and a beta of 1.22. The company has a fifty day moving average of $1.66 and a 200-day moving average of $2.65. Sutro Biopharma has a one year low of $0.76 and a one year high of $6.13.
Sutro Biopharma (NASDAQ:STRO - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The company had revenue of $14.00 million during the quarter, compared to the consensus estimate of $10.44 million. During the same quarter last year, the business earned ($1.78) earnings per share. Research analysts predict that Sutro Biopharma will post -2.92 EPS for the current year.
Institutional Trading of Sutro Biopharma
A number of hedge funds have recently modified their holdings of STRO. Vestal Point Capital LP acquired a new position in Sutro Biopharma during the fourth quarter valued at $4,729,000. Bank of Montreal Can purchased a new position in Sutro Biopharma during the 3rd quarter valued at about $2,852,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Sutro Biopharma in the 3rd quarter valued at about $1,512,000. Prudential Financial Inc. lifted its position in shares of Sutro Biopharma by 351.0% in the fourth quarter. Prudential Financial Inc. now owns 547,510 shares of the company's stock worth $1,007,000 after purchasing an additional 426,100 shares in the last quarter. Finally, Suvretta Capital Management LLC boosted its holdings in shares of Sutro Biopharma by 3.8% during the fourth quarter. Suvretta Capital Management LLC now owns 7,462,495 shares of the company's stock worth $13,731,000 after purchasing an additional 275,000 shares during the period. Hedge funds and other institutional investors own 96.99% of the company's stock.
About Sutro Biopharma
(
Get Free Report)
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Further Reading
Before you consider Sutro Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.
While Sutro Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
